Results 321 to 330 of about 1,046,081 (384)

Microglial reprogramming: a potential new frontier in enhancing immunotherapy for melanoma brain metastasis

Molecular Oncology, EarlyView.
Microglia act as tumor suppressors during brain metastasis colonization but shift to a tumor‐promoting role after melanoma brain metastases form. NF‐κB/RelA signaling emerges as a key driver of this phenotypic shift. Targeting this pathway reprograms microglia into a pro‐inflammatory state, enhancing antitumor immunity and immune checkpoint inhibitor ...
Noam Savion‐Gaiger, Dorin Bar‐Ziv, Harriet Kluger   +2 more
wiley   +1 more source

Reproductive health literacy scale: a tool to measure the effectiveness of health literacy training. [PDF]

Reprod Health
Rauf M, Goliaei Z, Machta L, Chang J, Thiel de Bocanegra H.   +4 more
europepmc   +1 more source

Healthcare service providers’ and facility administrators’ perspectives of the free maternal healthcare services policy in Malindi District, Kenya: a qualitative study [PDF]

Alma Ata Declaration, AO Ndep, B Russell, Central Bureau of Statistics, Ministry of Health Kenya, ORC Macro, D Wilkinson, Evaline Lang’at, F Moretti, G Mwabu, GPB Ogrinc, HS Galadanci, J Nzinga, JK Mbugua, Kenya National Bureau of Statistics & ICF MACRO, Kenya National Bureau of Statistics & ICF MACRO, L Gilson, L Mwanri, LC Steinhardt, LE Hatt, Lillian Mwanri, LL Levers, M El-Khoury, M Nimpagaritse, Ministry of Health, MK Mwamuye, Municipal Council of Malindi, P Liamputtong, Republic of Kenya, RL Chatburn, S Penfold, S Ritchie, S Thaddeus, S Witter, S Witter, S Witter, World Health Organisation, World Health Organisation, World Health Organisation Regional Office for Africa, World Health Organization, ICM & FIGO. World Health Organization   +37 more
core   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

Online Misleading Information About Women's Reproductive Health: A Narrative Review. [PDF]

J Gen Intern Med
John JN, Gorman S, Scales D, Gorman J.
europepmc   +1 more source

How Canada can help global adolescent health mature [PDF]

Ashley Vandermorris, GC Patton, Zulfiqar A Bhutta   +2 more
core   +1 more source

Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

Molecular Oncology, EarlyView.
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani, Gilgi Friedlander, Gili Perry, Nora Balint‐Lahat, Shlomit Gilad, Dana Morzaev‐Sulzbach, Anjana Shenoy, Noa Bossel Ben‐Moshe, Anya Pavlovsky, Rinat Bernstein‐Molho, Eytan Domany, Iris Barshack, Tamar Geiger, Bella Kaufman, Einav Nili Gal‐Yam   +14 more
wiley   +1 more source

Fatty acid composition in the vaginal tract of cis-gender women: canary in coal mines for reproductive health? [PDF]

Lipids Health Dis
Dufresne K.
europepmc   +1 more source

Fertility awareness and attitudes towards parenthood among Danish university college students [PDF]

A Skoog Svanberg, A-N Yli-Kuha, BD Peterson, C Lampic, CHY Chan, D Vassard, DB Dunson, G Andersson, GA Sartorius, H Kang, H Leridon, Hanne Kristine Hegaard, I Delbaere, I Mogilevkina, J Balasch, J Stern, JC Daniluk, L Bunting, L Schmidt, L Schmidt, Lone Schmidt, M Mills, Mette Grønbæk Backhausen, Mette Juhl, Nina Olsén Sørensen, RM Silver, Signe Marcussen, SP Morgan, Statistics Denmark, Statistics Denmark, T Sobotka, T Tydén, Tanja Tydén, The European IVF-monitoring programme (EIM)   +33 more
core   +1 more source

MIF as an oncogenic driver of low‐heterogeneity melanomas

Molecular Oncology, EarlyView.
Shvefel and colleagues identified tumor‐secreted macrophage migration inhibitory factor (MIF) as an upregulated cytokine that mediates immune resistance in melanomas with low‐intratumoral heterogeneity. MIF and its functional paralogue D‐dopachrome tautomerase (D‐DT or MIF‐2) have overlapping but nonidentical signaling functions and are hypothesized to
Thuy T. Tran, Gabriela Athziri Sánchez‐Zuno, Rajan P. Kulkarni, Harriet M. Kluger, Richard Bucala   +4 more
wiley   +1 more source